Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. announced today that the humanized anti-soluble aggregated amyloid-beta (A?) monoclonal antibody "LEQEMBI®" has been ...

Cambridge, Massachusetts-based Biogen Inc. ( BIIB) discovers, develops, manufactures, and delivers therapies for treating ...

We’ve debated immigration since Native Americans encountered a group of migrants from England who decided to settle in ...

Biogen, Inc. is a biopharmaceutical company ... and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

But with new technology based on branched silencing RNA licensed from the University of Massachusetts Medical ... The partnership with Biogen will develop RNAi therapeutics for multiple targets ...

Happenings in Boston’s life sciences ecosystem this past week include the departure of a general partner from Apple Tree Partners for another firm, Kronos Bio seeks "strategic alternatives" and new ...

A coffee shop in Middleborough, Massachusetts, went viral overnight for offering free coffee to customers who entered the shop while dancing. A video of customers participating in the promotion ...

Needham sees no near-term catalysts for Biogen The brokerage said it sees Leqembi’s sales projection “likely to continue to be a slow grind, rather than see an inflection point” and said it ...

Recent rumours that Biogen was about to acquired by Samsung proved unfounded, but it turns out a deal has been in preparation. The South Korean firm just agreed to buy Biogen out of their ...

Sage Therapeutics discontinued development of its lead candidate dalzanemdor after a third clinical failure, leading analysts ...